Nakamura Nobuhiko, Morishita Tetsuji, Hayashi Hiromi, Okabe Motohito, Nakasone Hideki, Uchida Naoyuki, Doki Noriko, Fukuda Takahiro, Yoshihara Satoshi, Tanaka Masatsugu, Nishida Tetsuya, Hasegawa Yuta, Matsuoka Ken-Ichi, Sawa Masashi, Eto Tetsuya, Onizuka Makoto, Katayama Yuta, Kato Koji, Ishimaru Fumihiko, Tabuchi Ken, Atsuta Yoshiko, Kanemura Nobuhiro, Teshima Takanori
Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Department of Internal Medicine, Matsunami General Hospital, Gifu, Japan.
Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02588-0.
The SARS-CoV-2 pandemic disrupted healthcare systems worldwide, particularly affecting hematopoietic stem cell transplantation (HSCT) activities. Understanding the impact of the SARS-CoV-2 pandemic on transplant practices, especially in Japan, where cord blood transplantation (CBT) is prevalent, is crucial. A total of 40,444 allogeneic HSCT cases in Japan between 2011 and 2021 were examined using an interrupted time series analysis to assess the impact of COVID-19 on CBT utilization. Following the SARS-CoV-2 pandemic, CBT cases demonstrated a significant increase (11.06 [95% confidence interval (CI): 1.87 to 20.25] cases per month), whereas bone marrow transplantation cases decreased, by 10.74 cases per month (95% CI, -19.84 to -1.63 cases per month). Total HSCT cases remained stable with a level change of 5.47 cases per month (95% CI, -10.07 to 21.01 cases per month) and a trend change of -1.11 cases per month (95% CI, -2.22 to 0.004 cases per month). The interrupted time series analysis showed significantly increased CBT cases in Japan, highlighting its crucial role as an alternative transplant source during the pandemic. CBT offset the impact of the decrease in bone marrow transplantation and contributed to the maintenance of HSCT activity in Japan during the unprecedented crisis.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行扰乱了全球医疗系统，尤其影响了造血干细胞移植（HSCT）活动。了解SARS-CoV-2大流行对移植实践的影响至关重要，特别是在日本，脐带血移植（CBT）很普遍。本研究使用中断时间序列分析方法，对2011年至2021年期间日本的40444例异基因HSCT病例进行了分析，以评估2019冠状病毒病（COVID-19）对CBT使用情况的影响。在SARS-CoV-2大流行之后，CBT病例显著增加（每月增加11.06例[95%置信区间（CI）：1.87至20.25例]），而骨髓移植病例减少，每月减少10.74例（95%CI，-19.84至-1.63例/月）。HSCT病例总数保持稳定，每月水平变化为5.47例（95%CI，-10.07至21.01例/月），趋势变化为每月-1.11例（95%CI，-2.22至0.004例/月）。中断时间序列分析显示，日本的CBT病例显著增加，突显了其在大流行期间作为替代移植来源的关键作用。CBT抵消了骨髓移植减少的影响，并在这场前所未有的危机中有助于维持日本的HSCT活动。
